Inogen, Inc.
INGNHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Inogen, Inc. (INGN) is listed under Medical Devices. Valued at $188.4M, INGN is a micro-cap name in its sector. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Market Cap
$188.4M
Beta
1.50
P/E (TTM)
—
P/E (Fwd)
-44.38
EPS (TTM)
$-0.93
EPS (Fwd)
$-0.16
ROE
-13.1%
ROA
-5.8%
Cash
$105.5M
Total Debt
$15.8M
Free CF
-$1.8M
52W Change
-19.0%
Annual Financials
Cash vs Debt
Where INGN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, INGN finished 5.14% above its 150-day moving average ($6.23) and 5.48% above its 200-day moving average ($6.21). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INGN overbought or oversold?
At the October 20, 2026 close, INGN's RSI(14) was 73.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $105.5M in cash comfortably exceeding the $15.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$1.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -13.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $377.2M (2022) to $348.7M (2025).
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing INGN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.